6090 Stock Overview
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Human Metabolome Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥607.00 |
| 52 Week High | JP¥720.00 |
| 52 Week Low | JP¥501.00 |
| Beta | 0.51 |
| 1 Month Change | 0.50% |
| 3 Month Change | -1.94% |
| 1 Year Change | 0.16% |
| 3 Year Change | -3.96% |
| 5 Year Change | -25.15% |
| Change since IPO | -78.64% |
Recent News & Updates
Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 03
Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market
Aug 06Recent updates
Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 03Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market
Aug 06Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
Jun 07Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
May 22Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year
Apr 06Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00
Mar 23Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00
Feb 26Shareholder Returns
| 6090 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | 0.2% | -2.9% | -1.5% |
| 1Y | 0.2% | -13.7% | 13.7% |
Return vs Industry: 6090 exceeded the JP Life Sciences industry which returned -13.7% over the past year.
Return vs Market: 6090 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility
| 6090 volatility | |
|---|---|
| 6090 Average Weekly Movement | 2.7% |
| Life Sciences Industry Average Movement | 5.5% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 6090 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 6090's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 58 | Yasuhiro Ohata | www.humanmetabolome.com |
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma.
Human Metabolome Technologies, Inc. Fundamentals Summary
| 6090 fundamental statistics | |
|---|---|
| Market cap | JP¥3.59b |
| Earnings (TTM) | JP¥246.00m |
| Revenue (TTM) | JP¥1.38b |
14.6x
P/E Ratio2.6x
P/S RatioIs 6090 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6090 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.38b |
| Cost of Revenue | JP¥483.00m |
| Gross Profit | JP¥901.00m |
| Other Expenses | JP¥655.00m |
| Earnings | JP¥246.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 41.56 |
| Gross Margin | 65.10% |
| Net Profit Margin | 17.77% |
| Debt/Equity Ratio | 11.0% |
How did 6090 perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 06:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Human Metabolome Technologies, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |